Early glucocorticoid withdrawal in severe ANCA‐associated vasculitis treated with combination cyclophosphamide and rituximab: a single‐centre case series

Glucocorticoid (GC)‐related toxicity remains a major challenge in anti‐neutrophil cytoplasm antibody‐associated vasculitis (AAV). We report five cases of newly diagnosed severe AAV treated with combination cyclophosphamide and rituximab, with the goal of ceasing GCs within 4 weeks. All patients achieved complete remission, with one relapse during follow‐up. All remained GC‐free at a median follow‐up of 12 months. The regimen was well tolerated despite severe renal impairment. These findings support the feasibility of early GC withdrawal in organ‐threatening AAV.